@article{42f67191dd014d8d8e13f4ebe297298d,
title = "Nuclease-mediated depletion biases in ribosome footprint profiling libraries",
abstract = "Ribosome footprint profiling is a high-throughput sequencing-based technique that provides detailed and global views of translation in living cells. An essential part of this technology is removal of unwanted, normally very abundant, ribosomal RNA sequences that dominate libraries and increase sequencing costs. The most effective commercial solution (Ribo-Zero) has been discontinued as a standalone product and a number of new, experimentally distinct commercial applications have emerged on the market. Here we evaluated several commercially available alternatives designed for RNA-seq of human samples and find them generally unsuitable for ribosome footprint profiling. We instead recommend the use of custom-designed biotinylated oligos, which were widely used in early ribosome profiling studies. Importantly, we warn that depletion solutions based on targeted nuclease cleavage significantly perturb the high-resolution information that can be derived from the data, and thus do not recommend their use for any applications that require precise determination of the ends of RNA fragments.",
keywords = "RNA-seq, RRNA depletion, Ribo-Zero, Ribo-seq, Ribosome profiling",
author = "Boris Zinshteyn and Wangen, {Jamie R.} and Boyang, {H. U.A.} and Rachel Green",
note = "Funding Information: We thank David Mohr and the Johns Hopkins Genetic Resources Core Facility for sequencing assistance. We thank Scott Kuersten (Illumina) for providing Ribo-Zero Plus material as well as advice on its use, and Sezen Meydan for suggestions on the use of Qiagen FastSelect. This work was funded by the National Institutes of Health, National Institute of General Medical Funding Information: We thank David Mohr and the Johns Hopkins Genetic Resources Core Facility for sequencing assistance. We thank Scott Kuersten (Illumina) for providing Ribo-Zero Plus material as well as advice on its use, and Sezen Meydan for suggestions on the use of Qiagen FastSelect. This work was funded by the National Institutes of Health, National Institute of General Medical Sciences (2R37GM059425-14 to R.G.; 5K99GM135450-02 to B.Z.), Howard Hughes Medical Institute (HHMI) (R.G.), and the Cystic Fibrosis Foundation (GREEN16G0). B.Z. was an HHMI fellow of the Damon Runyon Cancer Research Foundation (DRG-2250-16) for a portion of this study. Publisher Copyright: {\textcopyright} 2020 Zinshteyn et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",
year = "2020",
month = oct,
doi = "10.1261/rna.075523.120",
language = "English (US)",
volume = "26",
pages = "1481--1488",
journal = "RNA",
issn = "1355-8382",
publisher = "Cold Spring Harbor Laboratory Press",
number = "10",
}